• Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU
  • Seven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free
  • Barzolvolimab has potential to shift treatment goals from symptom control to disease modification
  • Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026